

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 January 2005 (06.01.2005)


PCT

(10) International Publication Number  
**WO 2005/000197 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K**
- (21) International Application Number:  
PCT/US2004/011297
- (22) International Filing Date: 12 April 2004 (12.04.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/462,554 11 April 2003 (11.04.2003) US
- (71) Applicant (for all designated States except US): **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; Office of Technology Management, 185 Berry Street, Suite 4603, San Francisco, CA 94107 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **TAUNTON, Jack** [US/US]; 2920-22nd Street, San Francisco, CA 94110 (US). **COHEN, Michael** [US/US]; 166 Locksley Avenue, Apt. 1, San Francisco, CA 94122 (US). **SHOKAT, Kevan** [US/US]; 783-35th Avenue, San Francisco, CA 94121 (US). **ZHANG, Chao** [CN/US]; 1515-27th Avenue, San Francisco, CA 94122 (US).
- (74) Agents: **ACKERMAN, Joel, G. et al.**; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111-3834 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**  
— of inventorship (Rule 4.17(iv)) for US only

[Continued on next page]

(54) Title: **SELECTIVE SERINE/THREONINE KINASE INHIBITORS**



\*Reagents and conditions: (i) NBS, DMF, rt (ii) Pd(PPh<sub>3</sub>)<sub>4</sub>, α-(ethoxyvinyl)tin, toluene, reflux. (iii) NBS, NaHCO<sub>3</sub>, H<sub>2</sub>O, DMF, -20 °C. (iv) 1:3 1N HBr:THF, 0 °C to rt. (v) NCS, NaHCO<sub>3</sub>, H<sub>2</sub>O, MeCN, rt. (vi) 1:3 1N HCl:THF, 0 °C to rt. (vii) KF, [bmim][BF<sub>4</sub>], H<sub>2</sub>O, MeCN, 60 °C.

(57) Abstract: Inhibition of protein kinases having one or more cysteine residues within the ATP binding site is effected by contacting the kinase, per se or in a cell or subject, with an inhibitory-effective amount of a compound having a heterocyclic core structure comprised of two or more fused rings containing at least one nitrogen ring atom, and an electrophilic substituent that is capable of reacting with a cysteine residue within the ATP binding site of a kinase. Preferred compounds include certain pyrrolopyrimidines and oxindoles having such an electrophilic substituent and optionally an aromatic or heteroaromatic substituent that is capable of interacting with a threonine or smaller residue located in the gatekeeper position of the kinase. Kinases lacking such cysteine residues may be engineered or modified so that they are capable of being inhibited by such compounds by replacing a valine or other amino acid residue within the ATP binding site by a cysteine residue.



**Published:**

— without international search report and to be republished  
upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*